Virtual Reliability System for Visual Spatial Attention Evaluation in Stroke Patients

April 11, 2022 updated by: National Taiwan University Hospital

Application of a Virtual Reliability System in the Evaluation of the Visual Spatial Attention in Stroke Patients

The researchers designed a software based on a head-mounted displays for virtual reality (HMD-VR) to evaluate the reaction time to stimuli presented at right or left visual field. The study will recruit 100 stroke patients with hemisphere lesions (50 patients for right and left each) and 100 age-matched healthy controls. The participants will conduct a simple reaction time task in VR, with stimuli designated in the left or right hemi-field. The stroke patients will also received traditional tests for hemi-neglect. Test-retest reliability of the assessment will be conducted in a subset of the control group. The stroke patients will be followed in 3-4 weeks.

Study Overview

Status

Enrolling by invitation

Detailed Description

The researchers designed a software based on a head-mounted displays for virtual reality (HMD-VR) to evaluate the reaction time to stimuli presented at right or left visual field. The study will recruit 100 stroke patients with hemisphere lesions (50 patients for right and left hemisphere each) and 100 age-matched healthy controls. The participants will conduct a simple reaction time task in VR, with stimuli designated in the left or right hemi-field. The stroke patients will also receive traditional tests for hemi-neglect. The researchers will also collect the demographic data, cognition function and daily activity function. Test-retest reliability of the assessment will be conducted in a subset of the control group. The stroke patients will be followed in 3-4 weeks. The researchers will compare the results of a traditional hemi-neglect tests and VR-based tests and their changes in two occasions.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taipei, Taiwan
        • National Taiwan University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

outpatient and inpatient rehabilitation unit in a medical center

Description

Inclusion Criteria for stroke patients:

  1. aged at least 20 years old
  2. diagnosed with stroke involving unilateral MCA and ACA territory
  3. with unilateral upper limb with normal function
  4. neurologically and medically stable.

Inclusion criteria for control group:

1) healthy adults, age-matched to stroke patients

Exclusion Criteria for both groups:

  1. with history of neurological or psychiatric conditions other than stroke;
  2. significant cognitive or speech problems that cause difficulties to cooperate with testing;
  3. significant visual problems (such as color blindness, visual loss, cataract, glaucoma or other major eye condition)
  4. upper limb musculoskeletal disorders to cause difficulties to use the keyboard or controller;
  5. history of seizure, vestibular dysfunction or vertigo
  6. can't tolerate HMD-VR

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
stroke (right)
stroke patient with lesions at right hemisphere
stroke (left)
stroke patient with lesions at left hemisphere
control
age-matched group for the stroke patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
reaction time
Time Frame: 4 weeks
reaction time to the stimuli presented in the right or left hemi-field with VR software
4 weeks
hemineglect tests
Time Frame: 4 weeks
Paper-based behavior inattention test (BIT)
4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ADL
Time Frame: 4 weeks
activities of daily living function evaluated by barthel index
4 weeks
cognition
Time Frame: 4 weeks
using Montreal Cognitive Assessment (MoCA)
4 weeks
cybersickness
Time Frame: 1 day
using Simulator Sickness Questionnaire (SSQ)
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Huey-Wen Liang, MD, National Taiwan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 24, 2021

Primary Completion (Anticipated)

December 31, 2022

Study Completion (Anticipated)

December 31, 2022

Study Registration Dates

First Submitted

April 11, 2022

First Submitted That Met QC Criteria

April 11, 2022

First Posted (Actual)

April 18, 2022

Study Record Updates

Last Update Posted (Actual)

April 18, 2022

Last Update Submitted That Met QC Criteria

April 11, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke Sequelae

3
Subscribe